Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy

Immunological Investigations

Volumn 46, Issue 3, 2017, Pages 221-238

  Maccalli, Cristina ^a   Parmiani, Giorgio ^b   Ferrone, Soldano ^c  

^a SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cancer initiating cell markers; cancer initiating cells; chimeric antigen receptor (CAR) T cells; immune checkpoint molecules; immunological profile; immunosuppressive properties; immunotherapy; neo epitopes; T cell responses

Indexed keywords

TUMOR ANTIGEN;

ANTIGEN RECOGNITION; CANCER CELL; CANCER CELL DESTRUCTION; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER INITIATING CELL; CELL STRUCTURE; CELLULAR IMMUNITY; HLA SYSTEM; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOSURVEILLANCE; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANIMAL; CANCER STEM CELL; CARCINOGENESIS; CLINICAL TRIAL (TOPIC); DISEASE MODEL; IMMUNOLOGY; IMMUNOTHERAPY; MOUSE; NEOPLASMS; PHYSIOLOGY; PROCEDURES; TUMOR ESCAPE;

ANIMALS; CARCINOGENESIS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOLOGIC SURVEILLANCE; IMMUNOMODULATION; IMMUNOTHERAPY; MICE; NEOPLASMS; NEOPLASTIC STEM CELLS; TUMOR ESCAPE;

EID: 85016075617     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.1080/08820139.2017.1280051     Document Type: Review

References (132)

1. Acloque H, Adams MS, Fishwick K, et al. 2009. Epithelial-mesenchymal transitions:the importance of changing cell state in development and disease. J Clin Invest 119(6),1438–1449.
2. Al-Ejeh F, Smart CE, Morrison BJ, et al. 2011. Breast cancer stem cells:treatment resistance and therapeutic opportunities. Carcinogenesis, 32(5),650–658.
3. Bao S, Wu Q, McLendon RE, et al. 2006. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 444(7120),756–760.
4. Beard RE, Zheng Z, Lagisetty KH, et al. 2014. Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells. J Immunother Cancer, 2, 25.
5. Beatty GL, Gladney WL., 2015. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res, 21(4),687–692.
6. Bindea G, Mlecnik B, Angell HK, Galon J., 2014. The immune landscape of human tumors:Implications for cancer immunotherapy. Oncoimmunology, 3(1), e27456.
7. Bindea G, Mlecnik B, Fridman WH, Galon J., 2011. The prognostic impact of anti-cancer immune response:a novel classification of cancer patients. Semin Immunopathol, 33(4),335–340.
8. Brown CE., Badie B, Barish ME, et al. 2015. Bioactivity and safety of IL13Ralpha2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin Cancer Res, 21(18),4062–4072.
9. Brown CE, Starr R, Aguilar B, et al. 2012. Stem-like tumor-initiating cells isolated from IL13Ralpha2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells. Clin Cancer Res, 18(8),2199–2209.
10. Burnet FM., 1970. The concept of immunological surveillance. Prog Exp Tumor Res, 13, 1–27.
11. Campoli M, Ferrone S, Wang X., 2010. Functional and clinical relevance of chondroitin sulfate proteoglycan 4. Adv Cancer Res, 109, 73–121.
12. Castriconi R, Daga A, Dondero A, et al. 2009. NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J Immunol, 182(6),3530–3539.
13. Catalano V, Eleuteri C, Campoccia G, et al. 2015. Resistance of Cancer Stem Cells to Cell-Mediated Immune Responses. In Bonavida B, Chouaib S, eds. Resistance of Cancer Cells to CTL-Mediated Immunotherapy, Resistance to Targeted Anti-Cancer Therapeutics. Cham, Switzerland:Springer International Publishing, 3–29.
14. Chaffer CL, Brennan JP, Slavin JL, et al. 2006. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis:role of fibroblast growth factor receptor-2. Cancer Res, 66(23),11271–11278.
15. Chaffer CL, Brueckmann I, Scheel C, et al. 2011. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci USA, 108(19),7950–7955.
16. Clarke MF, Dick JE, Dirks PB, et al. 2006. Cancer stem cells–perspectives on current status and future directions:AACR Workshop on cancer stem cells. Cancer Res, 66(19),9339–9344.
17. Clemente CG, Mihm MC, Jr., Bufalino R, et al. 1996. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer, 77(7),1303–1310.
18. Codony-Servat J, Rosell, R., 2015. Cancer stem cells and immunoresistance:clinical implications and solutions. Transl Lung Cancer Res, 4(6),689–703.
19. Dean M, Fojo T, Bates S., 2005. Tumour stem cells and drug resistance. Nat Rev Cancer, 5(4),275–284.
20. Diehn M, Clarke MF., 2006. Cancer stem cells and radiotherapy:new insights into tumor radioresistance. J Natl Cancer Inst, 98(24),1755–1757.
21. Di Tomaso T, Mazzoleni S, Wang E, et al. 2010. Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res, 16(3),800–813.
22. Engelmann K, Shen H, Finn OJ., 2008. MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1. Cancer Res, 68(7),2419–2426.
23. Finocchiaro G, Pellegatta S., 2016. Immunotherapy with dendritic cells loaded with glioblastoma stem cells:from preclinical to clinical studies. Cancer Immunol Immunother, 65(1),101–109.
24. Forshew T, Murtaza M, Parkinson C, et al. 2012. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 4(136),136ra168.
25. Francipane MG, Alea MP, Lombardo Y, et al. 2008. Crucial role of interleukin-4 in the survival of colon cancer stem cells. Cancer Res, 68(11),4022–4025.
26. Fuchs E., 2009. The tortoise and the hair:slow-cycling cells in the stem cell race. Cell 137(5),811–819.
27. Geldres C, Savoldo B, Hoyos V, et al. 2014. T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo. Clin Cancer Res, 20(4),962–971.
28. Ginestier C, Hur MH, Charafe-Jauffret E, et al. 2007. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell, 1(5),555–567.
29. Grau JJ, Mesia R, de la Iglesia-Vicente M, et al. 2016. Enrichment of cells with cancer stem cell-like markers in relapses of chemoresistant patients with locally advanced head and neck squamous cell carcinoma. Oncology, 90(5),267–272.
30. Gros A, Parkhurst MR, Tran E, et al. 2016. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med, 22(4),433–438.
31. Gubin MM, Artyomov MN, Mardis ER, Schreiber RD., 2015. Tumor neoantigens:building a framework for personalized cancer immunotherapy. J Clin Invest, 125(9),3413–3421.
32. Hadjimichael C, Chanoumidou K, Papadopoulou N, et al. 2015. Common stemness regulators of embryonic and cancer stem cells. World J Stem Cells, 7(9),1150–1184.
33. Hatiboglu MA, Wei J, Wu AS, Heimberger AB., 2010. Immune therapeutic targeting of glioma cancer stem cells. Target Oncol, 5(3),217–227.
34. Hinrichs CS, Rosenberg SA., 2014. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev, 257(1),56–71.
35. Hirohashi Y, Torigoe T, Tsukahara T, et al. 2016. Immune responses to human cancer stem-like cells/cancer-initiating cells. Cancer Sci, 107(1),12–17.
36. Hjelmeland AB, Rich JN., 2012. The quest for self-identity:not all cancer stem cells are the same. Clin Cancer Res, 18(13),3495–3498.
37. Hoey T, Yen WC, Axelrod F, et al. 2009. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell, 5(2),168–177.
38. Hua W, Yao Y, Chu Y, et al. 2011. The CD133+ tumor stem-like cell-associated antigen may elicit highly intense immune responses against human malignant glioma. J Neurooncol, 105(2),149–157.
39. Inoda S, Hirohashi Y, Torigoe T, et al. 2011. Cytotoxic T lymphocytes efficiently recognize human colon cancer stem-like cells. Am J Pathol, 178(4),1805–1813.
40. Irvin DK, Jouanneau E, Duvall G, et al. 2010. T cells enhance stem-like properties and conditional malignancy in gliomas. PLoS One, 5(6), e10974.
41. Ji J, Judkowski VA, Liu G, et al. 2014. Identification of novel human leukocyte antigen-A*0201-restricted, cytotoxic T lymphocyte epitopes on CD133 for cancer stem cell immunotherapy. Stem Cells Transl Med, 3(3),356–364.
42. Kano M, Tsukahara T, Emori M, et al. 2011. Autologous CTL response against cancer stem-like cells/cancer-initiating cells of bone malignant fibrous histiocytoma. Cancer Sci, 102(8),1443–1447.
43. Kemper K, Prasetyanti PR, De Lau W, et al. 2012. Monoclonal antibodies against Lgr5 identify human colorectal cancer stem cells. Stem Cells, 30(11),2378–2386.
44. Kim SY, Cho HS, Yang SH, et al. 2009. Soluble mediators from human neural stem cells play a critical role in suppression of T-cell activation and proliferation. J Neurosci Res, 87(10),2264–2272.
45. Kohrt HE, Tumeh PC, Benson D, et al. 2016. Immunodynamics:a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. J Immunother Cancer, 4, 15.
46. Kreiter S, Castle JC, Tureci O, Sahin U., 2012. Targeting the tumor mutanome for personalized vaccination therapy. Oncoimmunology, 1(5),768–769.
47. Kroemer G, Galluzzi L, Zitvogel L., 2013. Immunological effects of chemotherapy in spontaneous breast cancers. Oncoimmunology, 2(12), e27158.
48. Leger O, Johnson-Leger C, Jackson E, et al. 1994. The chondroitin sulfate proteoglycan NG2 is a tumour-specific antigen on the chemically induced rat chondrosarcoma HSN. Int J Cancer 58(5),700–705.
49. Li GH, Wei H, Lv SQ, et al. 2010. Knockdown of STAT3 expression by RNAi suppresses growth and induces apoptosis and differentiation in glioblastoma stem cells. Int J Oncol, 37(1),103–110.
50. Li SC, Vu LT, Ho HW, et al. 2012. Cancer stem cells from a rare form of glioblastoma multiforme involving the neurogenic ventricular wall. Cancer Cell Int, 12(1), 41.
51. Li Y, Laterra, J., 2012. Cancer stem cells:distinct entities or dynamically regulated phenotypes? Cancer Res, 72(3),576–580.
52. Li Z, Lee JW, Mukherjee D, et al. 2012. Immunotherapy targeting glioma stem cells–insights and perspectives. Expert Opin Biol Ther, 12(2),165–178.
53. Liu D, Martin V, Fueyo J, et al. 2010. Tie2/TEK modulates the interaction of glioma and brain tumor stem cells with endothelial cells and promotes an invasive phenotype. Oncotarget, 1(8),700–709.
54. Liu G, Yuan X, Zeng Z, et al. 2006. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer, 5, 67.
55. Ljujic B, Milovanovic M, Volarevic V, et al. 2013. Human mesenchymal stem cells creating an immunosuppressive environment and promote breast cancer in mice. Sci Rep, 3, 2298.
56. Maccalli C, De Maria R., 2015. Cancer stem cells:perspectives for therapeutic targeting. Cancer Immunol Immunother, 64(1),91–97.
57. Maccalli C, Volonte A, Cimminiello C, Parmiani G., 2014. Immunology of cancer stem cells in solid tumours. A review. Eur J Cancer, 50(3),649–655.
58. Maciag PC, Seavey MM, Pan ZK, et al. 2008. Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. Cancer Res, 68(19),8066–8075.
59. Malanchi I, Santamaria-Martinez A, Susanto E, et al. 2012. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 481(7379),85–89.
60. Mani SA, Guo W, Liao MJ, et al. 2008. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell, 133(4),704–715.
61. Marabelle A, Gray J., 2015. Tumor-targeted and immune-targeted monoclonal antibodies:Going from passive to active immunotherapy. Pediatr Blood Cancer, 62(8),1317–1325.
62. Marabelle A, Routy B, Michels J, et al. 2016. Prime time for immune-checkpoint targeted therapy at ASCO 2015. Oncoimmunology, 5(3), e1068494.
63. Maugeri-Sacca M, Vigneri P, De Maria R., 2011. Cancer stem cells and chemosensitivity. Clin Cancer Res, 17(15),4942–4947.
64. McGranahan N, Furness AJ Rosenthal, et al. 2016. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science, 351 (6280),1463–1469.
65. Mennonna D, Maccalli C, Romano MC, et al. 2015. T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genes. Gut, pii:gutjnl-2015-309453; doi:10.1136/gutjnl-2015-309453 [Epub ahead of print].
66. Michaud NR, Wang Y, McEachern KA, et al. 2014. Novel neutralizing hedgehog antibody MEDI-5304 exhibits antitumor activity by inhibiting paracrine hedgehog signaling. Mol Cancer Ther, 13(2),386–398.
67. Mihm MC, Jr., Clemente CG, Cascinelli N., 1996. Tumor infiltrating lymphocytes in lymph node melanoma metastases:a histopathologic prognostic indicator and an expression of local immune response. Lab Invest, 74(1),43–47.
68. Mitra M, Kandalam M, Harilal A, et al. 2012. EpCAM is a putative stem marker in retinoblastoma and an effective target for T-cell-mediated immunotherapy. Mol Vis, 18, 290–308.
69. Mittelman A, Chen ZJ, Yang H, et al. 1992. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23:induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci USA. 89(2),466–470.
70. Morel AP, Lievre M, Thomas C, et al. 2008. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One, 3(8), e2888.
71. Morgan, RA, Johnson LA, Davis JL, et al. 2012. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther, 23(10),1043–1053.
72. Morita R, Nishizawa S, Torigoe T, et al. 2014. Heat shock protein DNAJB8 is a novel target for immunotherapy of colon cancer-initiating cells. Cancer Sci, 105(4),389–395.
73. Moucadel V, Prudent R, Sautel CF, et al. 2011. Antitumoral activity of allosteric inhibitors of protein kinase CK2. Oncotarget, 2(12),997–1010.
74. Naidoo J, Page DB, Wolchok JD., 2014. Immune checkpoint blockade. Hematol Oncol Clin North Am, 28(3),585–600.
75. Naidoo J, Page DB, Wolchok JD., 2014. Immune modulation for cancer therapy. Br J Cancer, 111(12),2214–2219.
76. Nejak-Bowen KN, Monga SP., 2011. Beta-catenin signaling, liver regeneration and hepatocellular cancer:sorting the good from the bad. Semin Cancer Biol, 21(1),44–58.
77. Nervi C, De Marinis E, Codacci-Pisanelli G., 2015. Epigenetic treatment of solid tumours:a review of clinical trials. Clin Epigenetics, 7, 127.
78. Ning N, Pan Q, Zheng F, et al. 2012. Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res, 72(7),1853–1864.
79. Ortega CE, Seidner Y, Dominguez I., 2014. Mining CK2 in cancer. PLoS One, 9(12), e115609.
80. Pardoll DM., 2012. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 12(4),252–264.
81. Park TS, Donnenberg VS, Donnenberg AD, et al. 2014. Dynamic interactions between cancer stem cells and their stromal partners. Curr Pathobiol Rep, 2(1),41–52.
82. Parmiani G, De Filippo A, Novellino L, Castelli C., 2007. Unique human tumor antigens:immunobiology and use in clinical trials. J Immunol, 178(4),1975–1979.
83. Parmiani G, Maccalli C, Maio M., 2015. Integrating immune checkpoint blockade with anti-neo/mutated antigens reactivity to increase the clinical outcome of immunotherapy. Vaccines (Basel), 3(2),420–428.
84. Parmiani G, Russo V, Maccalli C, et al. 2014. Peptide-based vaccines for cancer therapy. Hum Vaccin Immunother, 10(11),3175–3178.
85. Pellegatta S, Eoli M, Frigerio S, et al. 2013. The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates. Oncoimmunology, 2(3), e23401.
86. Peters S, Adjei AA., 2012. MET:a promising anticancer therapeutic target. Nat Rev Clin Oncol, 9(6),314–326.
87. Pietra G, Manzini C, Vitale M, et al. 2009. Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. Int Immunol, 21(7),793–801.
88. Pitt JM, Marabelle A, Eggermont A, et al. 2016. Targeting the tumor microenvironment:removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol, 27(8),1482–92.
89. Pol J, Vacchelli E, Aranda F, et al. 2015. Trial watch:immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology, 4(4), e1008866.
90. Price MA, Colvin Wanshura LE, Yang J, et al. 2011. CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma. Pigment Cell Melanoma Res, 24(6),1148–1157.
91. Privette Vinnedge LM, Kappes F, Nassar N, Wells SI., 2013. Stacking the DEK:from chromatin topology to cancer stem cells. Cell Cycle, 12(1),51–66.
92. Reya T, Morrison SJ, Clarke MF, Weissman IL., 2001. Stem cells, cancer, and cancer stem cells. Nature, 414(6859),105–111.
93. Riccardo F, Iussich S, Maniscalco L, et al. 2014. CSPG4-specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA. Clin Cancer Res, 20(14),3753–3762.
94. Ricci-Vitiani L, Pallini R, Larocca LM, et al. 2008. Mesenchymal differentiation of glioblastoma stem cells. Cell Death Differ, 15(9),1491–1498.
95. Rizvi NA, Hellmann MD, Snyder A, et al. 2015. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science, 348(6230),124–128.
96. Sabbatino F, Schwab JH, Ferrone S, Ferrone CR., 2013. Evolution of studies of HLA class I antigen processing machinery (APM) components in malignant cells. Clin Transpl, 453–463.
97. Schatton T, Frank MH., 2009. Antitumor immunity and cancer stem cells. Ann N Y Acad Sci, 1176, 154–169.
98. Scheel C, Weinberg RA., 2011. Phenotypic plasticity and epithelial-mesenchymal transitions in cancer and normal stem cells? Int J Cancer, 129(10),2310–2314.
99. Scheel C, Weinberg RA., 2012. Cancer stem cells and epithelial-mesenchymal transition:concepts and molecular links. Semin Cancer Biol. 22(5–6), 396–403.
100. Schmitz M, Temme A, Senner V, et al. 2007. Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy. Br J Cancer, 96(8),1293–1301.
101. Schumacher TN, Schreiber RD., 2015. Neoantigens in cancer immunotherapy. Science, 348(6230),69–74.
102. Siegel PM, Massague J., 2003. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer, 3(11),807–821.
103. Signore M, Pelacchi F, di Martino S, et al. 2014Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo. Cell Death Dis, 5, e1223.
104. Singh A, Greninger P, Rhodes D, et al. 2009. A gene expression signature associated with K-Ras addiction reveals regulators of EMT and tumor cell survival. Cancer Cell, 15(6),489–500.
105. Singh A, Settleman J., 2010. EMT, cancer stem cells and drug resistance:an emerging axis of evil in the war on cancer. Oncogene, 29(34),4741–4751.
106. Soltanian S, Matin MM., 2011. Cancer stem cells and cancer therapy. Tumour Biol, 32(3),425–440.
107. Sottoriva A, Sloot PM, Medema JP, Vermeulen L., 2010. Exploring cancer stem cell niche directed tumor growth. Cell Cycle, 9(8),1472–1479.
108. Stratford AL, Reipas K, Maxwell C, Dunn SE., 2010. Targeting tumour-initiating cells to improve the cure rates for triple-negative breast cancer. Expert Rev Mol Med, 12, e22.
109. Subramaniam PS, Whye DW, Efimenko E, et al. 2012. Targeting nonclassical oncogenes for therapy in T-ALL. Cancer Cell, 21(4),459–472.
110. Takeda N, Jain R, LeBoeuf MR, et al. 2011. Interconversion between intestinal stem cell populations in distinct niches. Science, 334(6061),1420–1424.
111. Tallerico R, Todaro M, Di Franco S, et al. 2013. Human NK cells selective targeting of colon cancer-initiating cells:a role for natural cytotoxicity receptors and MHC class I molecules. J Immunol, 190(5),2381–2390.
112. Todaro M, Gaggianesi M, Catalano V, et al. 2014. CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell, 14(3),342–356.
113. Trajanoski Z, Maccalli C, Mennonna D, et al. 2015. Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer. Cancer Immunol Immunother, 64(1),99–104.
114. Vermeulen L, De Sousa, EMF, van der Heijden M, et al. 2010. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol, 12(5),468–476.
115. Vik-Mo EO, Nyakas M, Mikkelsen BV, et al. 2013. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol Immunother, 62(9),1499–1509.
116. Visus C, Wang Y, Lozano-Leon A, et al. 2011. Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8(+) T cells. Clin Cancer Res, 17(19),6174–6184.
117. Visvader JE, Lindeman GJ., 2012. Cancer stem cells:current status and evolving complexities. Cell Stem Cell, 10(6),717–728.
118. Volonte’ A, Di Tomaso T, Spinelli M, et al. 2014. Cancer-initiating cells from colorectal cancer patients escape from T cell–mediated immunosurveillance in vitro through membrane–bound IL-4. J Immunol, 192(1),523–532.
119. Wan YY, Flavell RA., 2007. ‘Yin-Yang’ functions of transforming growth factor-beta and T regulatory cells in immune regulation. Immunol Rev, 220, 199–213.
120. Wang X, Katayama A, Wang Y, et al. 2011. Functional characterization of an scFv–Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4. Cancer Res, 71(24),7410–7422.
121. Wang X, Osada T, Wang Y, et al. 2010. CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. J Natl Cancer Inst, 102(19),1496–1512.
122. Wei J, Barr J, Kong LY, et al. 2010. Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther, 9(1),67–78.
123. Wicha MS, Liu S, Dontu G., 2006. Cancer stem cells:an old idea–a paradigm shift. Cancer Res, 66(4),1883–1890; discussion 1895–1886.
124. Wilson A, Laurenti E, Oser G, et al. 2008. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell, 135(6),1118–1129.
125. Wolfgang CL, Herman JM, Laheru DA,et al. 2013. Recent progress in pancreatic cancer. CA Cancer J Clin, 63(5),318–348.
126. Wu A, Wiesner S, Xiao J, et al. 2007. Expression of MHC I and NK ligands on human CD133+ glioma cells:possible targets of immunotherapy. J Neurooncol, 83(2),121–131.
127. Wu ZB, Qiu C, Zhang AL, et al. 2014. Glioma-associated antigen HEATR1 induces functional cytotoxic T lymphocytes in patients with glioma. J Immunol Res, 2014, 131494.
128. Yang JC, Rosenberg SA., 2016. Adoptive T-Cell Therapy for Cancer. Adv Immunol, 130, 279–294.
129. Yoshimura A, Muto G., 2011. TGF-beta function in immune suppression. Curr Top Microbiol Immunol, 350, 127–147.
130. Yuan J, Hegde PS, Clynes R, et al. 2016. Novel technologies and emerging biomarkers for personalized cancer immunotherapy. J Immunother Cancer, 4, 3.
131. Zhu X, Prasad S, Gaedicke S, et al. 2015. Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57. Oncotarget, 6(1),171–184.
132. Zhu Z, Khan MA, Weiler M, et al. 2014. Targeting self-renewal in high-grade brain tumors leads to loss of brain tumor stem cells and prolonged survival. Cell Stem Cell, 15(2),185–198.